Search Article 
 
Advanced search 
Official publication of the American Biodontics Society and the Center for Research and Education in Technology
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL HYPOTHESIS
Year : 2015  |  Volume : 6  |  Issue : 2  |  Page : 49-52

Possible neuroimmunomodulation therapy in T-cell-mediated oral diseases


1 Department of Oral and Maxillofacial Surgery, Saitama Medical University, Saitama, Japan
2 Division of Periodontology, Department of Oral Function, Kyushu Dental University, Fukuoka, Japan
3 Division of Molecular Signaling and Biochemistry, Department of Health Promotion, Kyushu Dental University, Fukuoka, Japan

Correspondence Address:
Dr. Tsuyoshi Sato
Department of Oral and Maxillofacial Surgery, Saitama Medical University, 38 Moro-hongou, Moroyama-machi, Iruma-gun, Saitama - 350-0495
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2155-8213.158472

Rights and Permissions

Introduction: Recurrent aphthous stomatitis and oral lichen planus are local chronic inflammatory diseases which are implicated in T cell-mediated immunity. According to the systematic review, there is insufficient evidence to support any specific treatment for T-cell mediated oral diseases. The hypothesis: In this paper, we propose a hypothesis that recurrent aphthous stomatitis and oral lichen planus can be treated with selective α7 subunit of nicotinic acetylcholine receptor (α7 -nAChR) agonists. Our hypothesis is supported by the following two facts. First, the pathophysiological conditions, T h 1/T h 17 cell activation and autonomic nervous system dysfunction, are observed in T-cell mediated oral diseases as well as in T-cell mediated systemic diseases such as rheumatoid arthritis. Second, the cholinergic anti-inflammatory pathway is inhibited in systemic T-cell mediated chronic inflammatory diseases. On the other hand, treatment with α7 -nAChR agonists which activate the cholinergic anti-inflammatory pathway suppresses neuroinflammation via inhibition of T h 1/T h 17 responses in animal model of systemic T-cell mediated chronic inflammatory diseases. We thus expect that selective α7 -nAChR agonists will be effective for the treatment of T-cell mediated oral diseases. Evaluation of the hypothesis: To test our hypothesis, we need to develop in vivo mouse model of T-cell mediated oral diseases. To evaluate the therapeutic effect of a selective α7 -nAChR agonist, we choose ABT-107 because of its safety and tolerability. We believe that the selective α7 -nAChR agonist, especially ABT-107, may be a therapeutic drug to treat T-cell mediated oral diseases.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1806    
    Printed46    
    Emailed0    
    PDF Downloaded275    
    Comments [Add]    

Recommend this journal